Abstract

BackgroundAnti-Müllerian hormone (AMH) is currently used as an ovarian reserve marker for individualized fertility counseling, but very little is known of individual AMH decline in women. This study assessed whether the decline trajectory of AMH is uniform for all women, and whether baseline age-specific AMH levels remain consistently high or low during this trajectory.MethodsA total of 3326 female participants from the population-based Doetinchem Cohort Study were followed with five visits over a 20-year period. Baseline age was 40 ± 10 years with a range of 20–59 years.AMH was measured in 12,929 stored plasma samples using the picoAMH assay (AnshLabs). Decline trajectories of AMH were studied with both chronological age and reproductive age, i.e., time to menopause. Multivariable linear mixed effects models characterized the individual AMH decline trajectories.ResultsThe overall rate of AMH decline accelerated after 40 years of age. Mixed models with varying age-specific AMH levels and decline rates provided the significantly best fit to the data, indicating that the fall in AMH levels over time does not follow a fixed pattern for individual women. AMH levels remained consistent along individual trajectories of age, with an intraclass correlation coefficient (ICC) of 0.87. The ICC of 0.32 for AMH trajectories with time to menopause expressed the large variation in AMH levels at a given time before the menopause. The differences between low and high age-specific AMH levels remained distinguishable, but became increasingly smaller with increasing chronological and reproductive age.ConclusionsThis is the first study to characterize individual AMH decline over a long time period and broad age range. The varying AMH decline rates do not support the premise of a uniform AMH decline trajectory. Although age-specific AMH levels remain consistently high or low with increasing age, the converging trajectories and variance of AMH levels at a given time before menopause shed doubt on the added value of AMH to represent individualized reproductive age.Electronic supplementary materialThe online version of this article (doi:10.1186/s12916-016-0699-y) contains supplementary material, which is available to authorized users.

Highlights

  • Anti-Müllerian hormone (AMH) is currently used as an ovarian reserve marker for individualized fertility counseling, but very little is known of individual AMH decline in women

  • A woman with a low AMH level would have a lower ovarian reserve, and a shorter time to menopause than a woman with a higher AMH level of the same age

  • This concept has found its way into clinical practice, as women are currently receiving personalized family planning or fertility treatment counseling based on their AMH levels

Read more

Summary

Introduction

Anti-Müllerian hormone (AMH) is currently used as an ovarian reserve marker for individualized fertility counseling, but very little is known of individual AMH decline in women. A woman with a low AMH level would have a lower ovarian reserve, and a shorter time to menopause than a woman with a higher AMH level of the same (chronological) age. This concept has found its way into clinical practice, as women are currently receiving personalized family planning or fertility treatment counseling based on their AMH levels. This may seem like an advancement in reproductive healthcare, evidence to support this practice is lacking. The individualized use of AMH as an indicator of the reproductive lifespan is still hampered by two main questions

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call